Pharmaceutical Regulatory Affairs Services

Regulatory strategy is a structured plan for obtaining regulatory approval for pharmaceutical, biotechnology, medical device, natural health, and consumer health products. It identifies the most appropriate regulatory pathway, required studies, submission requirements, agency interactions, and key development milestones.

• Developing a regulatory strategy early can help organizations:
• Select the appropriate approval pathway
• Identify required clinical and nonclinical studies
• Anticipate regulatory requirements
• Reduce development delays and costs
• Improve submission quality and approval success

Early planning is often most effective before significant investments are made in manufacturing, testing, or clinical development.

The appropriate regulatory pathway depends on several factors, including:

• Product classification
• Intended use or indication
• Active ingredients
• Route of administration
• Dosage form
• Existing clinical or scientific evidence
• Applicable regulatory requirements

For FDA drug approvals, common pathways include:

• NDA (505(b)(1)) for products supported by complete safety and efficacy data
• 505(b)(2) for products that can leverage existing published data or FDA findings
• ANDA for generic products demonstrating bioequivalence to an approved reference drug
• A regulatory assessment can help determine the most efficient route to market based on available data and product characteristics.

Requirements vary by jurisdiction and product type, but common submissions include:

• United States (FDA)

• IND (Investigational New Drug Application) submitted before initiating clinical trials
• NDA, 505(b)(2), or ANDA submitted to obtain marketing approval

• Canada (Health Canada)

• CTA (Clinical Trial Application) submitted before conducting clinical studies
• NDS (New Drug Submission) submitted to obtain market authorization
• DIN (Drug Identification Number) assigned to approved drug products marketed in Canada

These submissions typically include information related to product quality, manufacturing, safety, efficacy, and clinical development.

While requirements vary, regulatory submissions commonly contain:

• Administrative information
• Product quality and manufacturing data (CMC)
• Nonclinical studies
• Clinical studies
• Safety and efficacy data
• Labeling information
• Risk management documentation

The specific content depends on the product, jurisdiction, and regulatory pathway being pursued.

CMC (Chemistry, Manufacturing and Controls) documentation demonstrates that a product can be consistently manufactured according to appropriate quality standards.

Typical CMC information includes:

• Manufacturing processes
• Product specifications
• Stability data
• Analytical methods
• Packaging
• Quality controls

Much of this information is included in Module 3 of the Common Technical Document (CTD), the global quality section used in many regulatory submissions.

In some cases, manufacturers also rely on Drug Master Files (DMFs), which contain confidential information about facilities, materials, components, or manufacturing processes while protecting proprietary data.

Regulatory responsibilities continue after approval through post-approval regulatory compliance, which may include:

• Manufacturing changes
• Labeling updates
• Safety reporting
• Product variations
• Annual reports
• License renewals
• Regulatory inspections

It is important to note that approval in one country does not automatically grant approval in another. Agencies such as the FDA and Health Canada have different requirements, review processes, and administrative procedures. Companies typically must submit separate applications and may need additional labeling or supporting data before a product can be marketed in another jurisdiction.